CARsgen Therapeutics Holdings Limited (2171.HK)

4,800 -0,100 (-2,04%) Börsenschluss: 04:08PM HKT

CARsgen Therapeutics Holdings Limited

No. 466 Yindu Road
1st Floor Building 2 Xuhui District
Shanghai
China
86 21 6450 1828
https://www.carsgen.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 516

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Zonghai Li M.D., Ph.D.	Co-Founder, CEO, Chief Scientific Officer & Chairman of the Board	2,24M	N/A	1974
Dr. Huamao Wang Ph.D.	Co-Founder, COO & Executive Director	2,27M	N/A	1977
Dr. Hua Jiang	Executive Director	1,13M	N/A	1979
Dr. Hong Ma	Senior Vice President of Clinical Development	N/A	N/A	1972
Dr. Leigh Hsu	Senior Vice President of Business Development	N/A	N/A	1971
Dr. Raffaele Baffa M.D., Ph.D.	Chief Medical Officer	N/A	N/A	1960
Dr. Sylvie Peltier	Senior Vice President of Global Regulatory Affairs	N/A	N/A	1963
Mr. Wing Yat Lui	Company Secretary	N/A	N/A	1990

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in HKD.

Beschreibung

CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is developing autologous CAR-T product candidates, including CT053, which targets B-cell maturation antigen that is in pivotal Phase II/III trial for the treatment of relapsed/refractory multiple myeloma; CT041, which targets Claudin 18.2, is in Phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in Phase I clinical trial for gastric or pancreatic cancer; CT011, which is in Phase I clinical trial for patients with Glypican-3 positive IIIa hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial which targets G protein-coupled receptor class C group 5 member D for the treatment of R/R MM and relapsed/refractory primary plasma cell leukemia (R/R pPCL). It is also developing CT0180 and CT0181, which targets Glypican-3 that is in Phase I clinical trial for the treatment of hepatocellular carcinoma. In addition, the company is developing CT0590, which targets B-cell maturation antigen that is in Phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; CT048, which targets Claudin 18.2 that is in Phase I clinical trial for the treatment of gastric/gastroesophageal junction and pancreatic cancer; KJC2113 that targets mesothelin, as well as KJ-C2114 that are in pre-clinical stage for the treatment of solid tumors; and KJ-C2320 for acute myeloid leukemia that is in pre-clinical stage. Further, it develops AB011, which is in Phase I clinical trial for the treatment of gastric/pancreatic cancer. The company has a license agreement with HK Inno.N Corporation to develop and commercialize CT032 for the treatment of CD19. The company was founded in 2014 and is headquartered in Shanghai, China.

Corporate Governance

CARsgen Therapeutics Holdings Limiteds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.